Y Intercept Hong Kong Ltd Acquires New Position in United Therapeutics Co. (NASDAQ:UTHR)

Y Intercept Hong Kong Ltd purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 6,170 shares of the biotechnology company’s stock, valued at approximately $2,177,000.

A number of other large investors have also bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC increased its stake in United Therapeutics by 0.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares during the period. MBM Wealth Consultants LLC increased its stake in United Therapeutics by 1.9% in the 4th quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 41 shares during the period. UMB Bank n.a. increased its stake in United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 51 shares during the period. Access Investment Management LLC increased its stake in shares of United Therapeutics by 0.8% during the fourth quarter. Access Investment Management LLC now owns 7,335 shares of the biotechnology company’s stock valued at $2,588,000 after buying an additional 55 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.8 %

NASDAQ UTHR opened at $358.21 on Tuesday. The stock’s 50 day moving average is $362.39 and its 200 day moving average is $360.91. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The firm has a market capitalization of $15.99 billion, a PE ratio of 15.73, a P/E/G ratio of 0.97 and a beta of 0.57.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $956,195.85. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 114,164 shares of company stock valued at $41,671,293. 11.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research analyst reports. UBS Group boosted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.